What is Trombyl?
Trombyl is a brand name for acetylsalicylic acid (ASA), commonly known as aspirin, which is an antiplatelet medication used to prevent blood clots and reduce the risk of cardiovascular events.
Mechanism of Action
Trombyl (acetylsalicylic acid) works by irreversibly inhibiting platelet cyclooxygenase-1 (COX-1), specifically through acetylation of serine residue 529 within the enzyme 1. This permanently blocks the production of thromboxane A2 (TXA2), a potent stimulator of platelet aggregation and vasoconstriction 2, 3.
The key pharmacological features include:
- Irreversible platelet inhibition lasting the lifespan of the platelet (7-10 days)
- Rapid onset: Peak effect occurs within 15-20 minutes after oral administration 4
- Low bioavailability (40-50%) due to first-pass metabolism, but this is sufficient for antiplatelet effect 5
- Dose-dependent selectivity: Low doses preferentially inhibit platelet COX-1 over vascular COX-2 1
Clinical Uses
Secondary Prevention (Established Cardiovascular Disease)
Trombyl is indicated for long-term secondary prevention in all patients with established atherosclerotic cardiovascular disease 1. This includes:
- Prior myocardial infarction: Reduces vascular events by ~20 per 1000 patients treated for 2 years 1
- Unstable angina/acute coronary syndromes: Prevents ~50 vascular events per 1000 patients treated 1
- Prior stroke or TIA: Reduces recurrence by ~36 per 1000 patients over 2 years 1
- Peripheral arterial disease
- Stable angina pectoris: Reduces MI/sudden death by 34% 1, 2
Acute Treatment Settings
In acute situations requiring immediate antithrombotic effect:
- Acute coronary syndromes: Loading dose of 160-300 mg 1
- Acute myocardial infarction: 160 mg or higher 5
- Acute ischemic stroke: 160-300 mg loading dose 1, 5
Primary Prevention
Recent evidence (2018-2023) has shifted recommendations against routine use of ASA for primary prevention, particularly in older adults, due to bleeding risks outweighing benefits in low-risk populations 6, 7. The benefit-risk ratio is only favorable when cardiovascular event risk exceeds ~1.5% per year 1.
Optimal Dosing
The recommended maintenance dose for long-term cardiovascular prevention is 75-100 mg once daily 1. This represents the lowest effective dose that:
- Achieves complete inhibition of platelet TXA2 synthesis 1
- Minimizes gastrointestinal toxicity (dose-dependent) 1
- Maintains efficacy across multiple cardiovascular conditions 5
Higher doses (300-325 mg) provide no additional cardiovascular benefit but significantly increase bleeding risk 8, 5. The CURRENT-OASIS 7 trial definitively showed that high-dose ASA (300-325 mg/day) offered no advantage over low-dose (75-100 mg/day) for preventing cardiovascular events, but increased gastrointestinal bleeding 8.
Important Safety Considerations
Contraindications
- Active bleeding or hemophilia
- Severe uncontrolled hypertension
- Active peptic ulcer disease
- ASA allergy (asthma with nasal polyps)
- Active retinal bleeding 9
Bleeding Risk
The absolute excess of major bleeding is 1-2 events per 1000 patients per year with low-dose ASA 1. This risk must be weighed against cardiovascular benefits, which vary dramatically by baseline risk:
- High-risk patients (unstable angina): 50 events prevented per 1000/year vs 1-2 bleeding events 1
- Low-risk patients: 1-2 events prevented vs 1-2 bleeding events (unfavorable ratio) 1
Drug Interactions
Critical interaction with ibuprofen: Ibuprofen can block ASA's access to platelet COX-1, reducing antiplatelet effect 9. Patients should take:
- Ibuprofen ≥30 minutes after immediate-release ASA, OR
- Ibuprofen ≥8 hours before ASA 9
Proton pump inhibitors (PPIs): Routine use is NOT recommended with low-dose ASA (75-100 mg) due to lack of evidence 1. However, PPIs should be considered in patients with history of GI bleeding when antiplatelet therapy is necessary 9.
Combination Therapy
Dual antiplatelet therapy (ASA + clopidogrel) is indicated in specific high-risk situations 9, 8:
- Acute coronary syndromes: Reduces cardiovascular events by additional 20% vs ASA alone 1
- Post-PCI with stenting: Duration depends on stent type and bleeding risk 8, 7
- Short-term use (up to 21 days) after minor stroke/TIA 10
Long-term dual antiplatelet therapy increases major bleeding by ~1% absolute risk (3.7% vs 2.7% with ASA alone) and is NOT recommended for routine secondary prevention without specific indication 1.
Clinical Pearls
- Indefinite therapy: Once started for secondary prevention, ASA should be continued indefinitely unless contraindication develops 9
- Withdrawal risk: Discontinuation has been associated with recurrent ACS and stent thrombosis 9
- No monitoring required: Platelet function testing is not recommended for routine ASA therapy 1
- Enteric-coated formulations: May have lower bioavailability and inadequate platelet inhibition at low doses, particularly in heavier patients 5